TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1428569

Group type: EXPERIMENTAL
Intervention: Dopamine 2% (n = 11)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Haloperidol 0.5% (n = 11)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Bromocriptine 0.05% (n = 11)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Bromocriptine 0.1% (n = 10)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 43
Study: 6362409

Group type: EXPERIMENTAL
Intervention: Clotrimazole
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30660602

Group type: EXPERIMENTAL
Intervention: Autologous endometrial cell co-culture (AECC)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Conventional embryo culture medium
Number of subjects: 136
Study: 28275132

Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFA) overfeeding (+750 kcal/d) for 7 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFA) overfeeding (+750 kcal/d) for 7 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Combined data from SFA and PUFA groups
Number of subjects: 31
Study: 25850750

Group type: EXPERIMENTAL
Intervention: Selexipag (400 μg single dose)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Selexipag (600 μg multiple doses)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Selexipag (400 μg open-label dose)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: ACT-333679 (active metabolite)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 64
Study: 23944767

Group type: EXPERIMENTAL
Intervention: Nonsynonymous m.10398A>G mtDNA polymorphism (N=8)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Haplogroup H (N=13)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Haplogroup U (N=6)
Number of subjects: 39
Study: 21827706

Group type: EXPERIMENTAL
Intervention: Artemisinin-piperaquine (AP)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine phosphate (DHP)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 220
Study: 19259863

Group type: EXPERIMENTAL
Intervention: Breast cancer and physical activity message
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cardiovascular disease and physical activity message
Number of subjects: 200
Study: 17223112

Group type: EXPERIMENTAL
Intervention: rosuvastatin 5mg
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10mg
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20mg
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: bezafibrate 200mg
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: rosuvastatin (across dose range)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 154
Study: 15470853

Group type: EXPERIMENTAL
Intervention: Kinetic therapy (systematic mechanical rotation of patients with 40 degree turns)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standard turning (turning patients every 2 hours)
Number of subjects: 234
Study: 14601817

Group type: EXPERIMENTAL
Intervention: Contextually Relevant (CR) group practicing tying a necktie knot onto a mannequin
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Non-Contextually Relevant (NCR) group practicing tying a knot with a rope onto a wooden pole
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group that did not practice at all during the acquisition phase
Number of subjects: 56
Study: 9676143

Group type: EXPERIMENTAL
Intervention: Nucleotide-supplemented formulas
Number of subjects: 0
Study: 7915703

Group type: EXPERIMENTAL
Intervention: Short-term prazosin (2 mg orally)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Long-term prazosin (5 mg/12 hr for 3 months)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2642866

Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 769595

Group type: EXPERIMENTAL
Intervention: Intravenous atropine 0-3 mg given prior to surgery
Number of subjects: 78

Group type: COMPARATOR
Intervention: Droperidol 0-1 mg/kg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Atropine 0-6 mg intramuscularly followed by controlled ventilation
Number of subjects: 78
Study: 31036927

Group type: EXPERIMENTAL
Intervention: RCA-CVVH
Number of subjects: 56

Group type: COMPARATOR
Intervention: NA-CVVH
Number of subjects: 56
Study: 28926521

Group type: EXPERIMENTAL
Intervention: TNT009 (7 consecutive cohorts, 0.3-100 mg/kg single doses)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: TNT009 (2 consecutive cohorts, 30 and 60 mg/kg per infusion, 4 weekly infusions)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: TNT009
Number of subjects: 64
Study: 25800582

Group type: EXPERIMENTAL
Intervention: Early coronary angiography (CAG) performed on admission or within the first 6 hours after arrest; 252 patients (46%) received early CAG.
Number of subjects: 544

Group type: COMPARATOR
Intervention: Control group (no early CAG); 292 patients (54%) did not receive early CAG.
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Early coronary angiography (CAG)
Number of subjects: 544
Study: 24215780

Group type: EXPERIMENTAL
Intervention: Xylazine (1mg/kg IV bolus followed by 0.69 mg/kg/h IV CRI for 2h)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Romifidine (80 μg/kg IV bolus followed by 30 μg/kg/h IV CRI for 2h)
Number of subjects: 7
Study: 20698793

Group type: EXPERIMENTAL
Intervention: Standard exercise plus Wii bowling (Wii)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard exercise (SG)
Number of subjects: 34
Study: 19826293

Group type: EXPERIMENTAL
Intervention: Squat Training with Vibration (SQTV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Squat Training without Vibration (SQT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 30
Study: 17106926

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ACE-I; Perindopril 4 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment with interferon (IFN; 3 MU/L; 3 times a week) and ACE-I
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon (IFN) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (ACE-I alone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment with ACE-I and IFN
Number of subjects: 0
Study: 15619490

Group type: EXPERIMENTAL
Intervention: Valved port (PASV; Boston Scientific)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Nonvalved port (BardPort; Bard Access Systems)
Number of subjects: 73
Study: 11379810

Group type: EXPERIMENTAL
Intervention: BDP-extrafine (400 microg daily)
Number of subjects: 172

Group type: COMPARATOR
Intervention: FP (400 microg daily)
Number of subjects: 172
Study: 9223063

Group type: EXPERIMENTAL
Intervention: THA 50 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: THA 25 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 7955168

Group type: EXPERIMENTAL
Intervention: Albendazole candy 100 mg (single dose)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Albendazole 150 mg qd for two days
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Albendazole 200 mg qd for two days
Number of subjects: 456
Study: 3584957

Group type: EXPERIMENTAL
Intervention: Coping skills intervention (eight sessions of instruction and practice)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no specific intervention mentioned)
Number of subjects: 0
Study: 29895234

Group type: EXPERIMENTAL
Intervention: Running schedule focusing on running intensity (S-I)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Running schedule focusing on running volume (S-V)
Number of subjects: 447
Study: 28962608

Group type: EXPERIMENTAL
Intervention: 8 weeks of home-based exercise (individualised endurance and resistance exercise program and behaviour change coaching) and nurse-delivered symptom self-management intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 8 weeks of home-based exercise
Number of subjects: 92
Study: 24418865

Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment combined with 1% olopatadine ophthalmic solution
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0.03% tacrolimus ointment combined with placebo eye drops
Number of subjects: 21
Study: 23609838

Group type: EXPERIMENTAL
Intervention: L. reuteri NCIMB 30242
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 21039763

Group type: EXPERIMENTAL
Intervention: Pharmaceutical products with active substances classified by BCS
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Class 1 active substances
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Class 2 active substances
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Class 3 active substances
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Class 4 active substances
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Pharmaceutical products with intra-subject variability higher than predicted
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Comparisons between pharmaceutical products from the four BCS classes
Number of subjects: 124
Study: 18158176

Group type: EXPERIMENTAL
Intervention: Specific oral tolerance induction (SOTI)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Milk-free diet (Control group B)
Number of subjects: 97
Study: 17060064

Group type: EXPERIMENTAL
Intervention: Dihydropyridine (felodipine)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Diuretic (chlorthalidone)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (lisinopril)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Angiotensin blocker (valsartan)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group (diltiazem monotherapy)
Number of subjects: 211
Study: 12660448

Group type: EXPERIMENTAL
Intervention: Münster clamp technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 30
Study: 10936118

Group type: EXPERIMENTAL
Intervention: Salmeterol (42 microg) every 12 h in addition to standard therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (two puffs every 12 h) in addition to standard therapy
Number of subjects: 43
Study: 8813296

Group type: EXPERIMENTAL
Intervention: fast fluid‐attenuated inversion recovery (fast‐FLAIR)
Number of subjects: 7

Group type: COMPARATOR
Intervention: conventional spin-echo (CSE)
Number of subjects: 7
Study: 7827745

Group type: EXPERIMENTAL
Intervention: ordinary head pillow
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: heel protectors based on siliconized hollow fibers
Number of subjects: 40
Study: 3137488

Group type: EXPERIMENTAL
Intervention: Deprenyl (selegiline) for 2 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30115037

Group type: EXPERIMENTAL
Intervention: Voucher incentive (1 € coffee voucher)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Control group (no voucher)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Risk ratio
Number of subjects: 472
Study: 27917460

Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 180
Study: 26646534

Group type: EXPERIMENTAL
Intervention: Arthrokinematic approach-Hakata method (AKA-H)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Sham technique (S)
Number of subjects: 186
Study: 24012586

Group type: EXPERIMENTAL
Intervention: Treadmill (TM) training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 21711512

Group type: EXPERIMENTAL
Intervention: Active Myofascial Trigger Points (MTrPs)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Latent Myofascial Trigger Points (MTrPs)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: DASH score correlation
Number of subjects: 72
Study: 18590407

Group type: EXPERIMENTAL
Intervention: NSAIDs in addition to opioid analgesics
Number of subjects: 789

Group type: COMPARATOR
Intervention: Opioid analgesics alone
Number of subjects: 789
Study: 17136232

Group type: EXPERIMENTAL
Intervention: 40 ml of 0.5% lidocaine plus 20 mg propofol (Group P)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 40 ml of 0.5% lidocaine (Group C)
Number of subjects: 26
Study: 12824959

Group type: EXPERIMENTAL
Intervention: Talc powder
Number of subjects: 33

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 33
Study: 10682869

Group type: EXPERIMENTAL
Intervention: Calcium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin B6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evening primrose oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Herbal products
Number of subjects: 0
Study: 7595746

Group type: EXPERIMENTAL
Intervention: Etopophos (150 mg/m2, administered by constant rate infusion over 3.5 hours)
Number of subjects: 49

Group type: COMPARATOR
Intervention: VePesid (150 mg/m2, administered by constant rate infusion over 3.5 hours)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Etopophos and VePesid
Number of subjects: 49
Study: 2275328

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (0.04 mg.kg‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7001862

Group type: EXPERIMENTAL
Intervention: Alprenolol (non-selective beta-blocker)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Metoprolol (cardioselective beta 1-blocker)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 10
Study: 30797401

Group type: EXPERIMENTAL
Intervention: Referral to expedited Medicaid enrollment
Number of subjects: 3086

Group type: COMPARATOR
Intervention: No referral to expedited Medicaid enrollment
Number of subjects: 3086
Study: 28158932

Group type: EXPERIMENTAL
Intervention: Neonatal morbidity (NNM)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Cerebral ultrasound abnormalities
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Trial group allocation
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Birthweight ratio
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Infant sex
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Apgar score
Number of subjects: 402
Study: 26009829

Group type: EXPERIMENTAL
Intervention: Abacavir/Lamivudine (ABC/3TC)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Tenofovir/Emtricitabine (TDF/FTC)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted Atazanavir
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 269
Study: 22957993

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study: 21846551

Group type: EXPERIMENTAL
Intervention: TF rotary system
Number of subjects: 40

Group type: COMPARATOR
Intervention: K3 rotary system
Number of subjects: 40
Study: 19308727

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 17259500

Group type: EXPERIMENTAL
Intervention: Boric acid vaginal suppositories (600 mg/day for 14 days)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Oral fluconazole (150 mg single dose)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Overall mycological cure irrespective of Candida species
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Frequencies of yeast on direct microscopy
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Clinical symptoms and signs of VVC on the 15th day of treatment
Number of subjects: 112
Study: 15212357

Group type: EXPERIMENTAL
Intervention: Diode laser radiation (655 nm)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Explorer
Number of subjects: 40
Study: 11520725

Group type: COMPARATOR
Intervention: Nasal oxygen (2 L/min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) (mean 9.25 cm H(2)O)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Bilevel (mean 13.5/5.2 cm H(2)O)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) (mean pressure 7 to 9 cm H(2)O)
Number of subjects: 14
Study: 9663810

Group type: EXPERIMENTAL
Intervention: Moclobemide 450 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Selegiline 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7823668

Group type: EXPERIMENTAL
Intervention: Two blocks of additional intensification therapy
Number of subjects: 1612

Group type: COMPARATOR
Intervention: One block of intensification therapy at 5 weeks
Number of subjects: 1612

Group type: COMPARATOR
Intervention: One block of intensification therapy at 20 weeks
Number of subjects: 1612

Group type: COMPARATOR
Intervention: No intensification therapy
Number of subjects: 1612
Study: 2688033

Group type: EXPERIMENTAL
Intervention: Active specific immunotherapy (ASI) with an autologous tumor cell‐BCG vaccine
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Resection plus ASI
Number of subjects: 74

Group type: COMPARATOR
Intervention: Resection alone (control)
Number of subjects: 74
Study: 803910

Group type: EXPERIMENTAL
Intervention: Conventional plus vasopressin therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 60
Study: 31825647

Group type: EXPERIMENTAL
Intervention: Targeted, low-burden, and stepped invitation strategy
Number of subjects: 2012

Group type: COMPARATOR
Intervention: Control group with standard invitation materials
Number of subjects: 2012

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 2012

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 2012

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2012
Study: 31207009

Group type: EXPERIMENTAL
Intervention: Intermittent intrauterine balloon dilatation therapy at 2 weeks and 6 weeks after surgery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intermittent intrauterine balloon dilatation therapy
Number of subjects: 200
Study: 28416171

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mononuclear cells
Number of subjects: 28
Study: 25661990

Group type: EXPERIMENTAL
Intervention: Abstinence from marijuana
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continued marijuana use
Number of subjects: 0
Study: 23933032

Group type: EXPERIMENTAL
Intervention: Fixed dose combination capsule of Alfuzosin hydrochloride 10mg extended release and Solifenacin succinate 5mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individually administered Xatral XL 10mg tablets (Alfuzosin) and Vesicare 5mg tablets (Solifenacin)
Number of subjects: 0
Study: 22202235

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 8

Group type: COMPARATOR
Intervention: S-1/PSK
Number of subjects: 8
Study: 19089501

Group type: EXPERIMENTAL
Intervention: Informational support from physicians
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Emotional support from physicians
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Decision-making support from physicians
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Informational support at 2 months
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Informational and emotional support at 2 months
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Emotional support at 5 months
Number of subjects: 246
Study: 16752179

Group type: EXPERIMENTAL
Intervention: Meal 1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Meal 2
Number of subjects: 10
Study: 15182985

Group type: EXPERIMENTAL
Intervention: Ligacast
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Dynastab
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ligaflex
Number of subjects: 14
Study: 11043547

Group type: EXPERIMENTAL
Intervention: Repetitive peripheral magnetic stimulation (RPMS) treatment of the left forearm
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Attentional cueing
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no RPMS or verbal cueing)
Number of subjects: 14
Study: 9432635

Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg q.d. for 2 or 4 weeks)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Ranitidine (300 mg q.d. for 2 or 4 weeks)
Number of subjects: 326
Study: 8458295

Group type: EXPERIMENTAL
Intervention: Posteducational follow-up intervention via telephone contact
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no posteducational follow-up)
Number of subjects: 27
Study: 3885915

Group type: EXPERIMENTAL
Intervention: methylprednisolone, 30 mg/kg, every six hours for 48 hours
Number of subjects: 81

Group type: COMPARATOR
Intervention: mannitol placebo
Number of subjects: 81
Study: 31785387

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) - four applications
Number of subjects: 17

Group type: COMPARATOR
Intervention: Combination of metronidazole (MTZ) and amoxicillin (AMX) - 3 tablets each for 7 days
Number of subjects: 17
Study: 29437170

Group type: EXPERIMENTAL
Intervention: Sacha inchi oil (15 mL)
Number of subjects: 42
Study: 27920516

Group type: EXPERIMENTAL
Intervention: Care pathway (CP) for COPD
Number of subjects: 342

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 342
Study: 24683565

Group type: EXPERIMENTAL
Intervention: Immediate loading group (IL group)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional loading group (CL group)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study: 22111353

Group type: EXPERIMENTAL
Intervention: Low tidal volume group (7 ml x kg(‐1) predicted body weight), n = 8
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional tidal volume group (10 ml x kg(‐1) predicted body weight), n = 8
Number of subjects: 16